Send us a text

Jörn Schattenberg and Michelle Long join the Surfers to discuss similarities and differences between the NASH and hypercholesterolemia markets.

It has been common for industry advocates and financial analysts to discuss the potential for the NASH/NAFLD drug market in comparison to the statin market, but this overlooks differences in the conditions they treat (NASH vs. hypercholesterolemia), the diagnostics available and the health economic environment. This episode pinpoints these differences and addresses what they mean in terms of treating the disease and adopting new drugs. 

The group covers several important topics very quickly, with focus on pre-launch market development, testing metrics and why it matters which companies are coming to market first. One similarity: in the absence of approved medications, disease treatment rests heavily on improving healthy lifestyles, which is a challenging target no matter the disease.